test

Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions

Brain and Central Nervous System Tumors | Chemotherapeutic Agent Toxicity | Cognitive/Functional Effects | Neurotoxicity | Psychosocial Effects of Cancer and Its Treatment | Radiation Toxicity | Therapy-related Toxicity

Trial Phase

N/A

Trial Purpose and Description

Trial Purpose

RATIONALE: Collecting information over time from a series of tests may help doctors develop effective tests to measure neuropsychological and behavioral function in young patients with cancer.

PURPOSE: This clinical trial is studying neuropsychological and behavioral testing in young patients with medulloblastoma or supratentorial primitive neuroectodermal tumor (PNET).


Trial Description

OBJECTIVES:

  • To institute procedures to ensure a consistent, streamlined, and efficient administration of the neuropsychological and behavioral tests in a cooperative group setting in order to maximize compliance with a standardized assessment battery conducted at 3 standardized time points in children with medulloblastoma or supratentorial primitive neuroectodermal tumor (PNET).
  • To utilize a standardized battery of age-appropriate neuropsychological and behavioral tests in conjunction with COG Phase III clinical trials to evaluate cognitive, social, emotional, and behavioral functioning over time.

OUTLINE: This is a multicenter study.

Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery testing at 9, 30, and 60 months post-diagnosis in a 1-hour session conducted by a neuropsychologist or psychologist. The Battery consists of tests of intelligence, processing speed/attention, memory, language preference, general developmental progress, attention and behavior/social/emotional function, executive function, adoptive function, and quality of life. Additionally, parents complete a parent-report questionnaire to gather information about patient's function in terms of attention, memory, executive abilities, and behavioral, social, and emotional adaption.

Participation Guidelines

Age:
3 Years - 21 Years
Gender:
Both

Eligibility Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed diagnosis of medulloblastoma or supratentorial primitive
neuroectodermal tumor (PNET)

- Must be currently enrolled on a COG therapeutic study that aims to examine
neuropsychological, social, emotional, and/or behavioral functioning

PATIENT CHARACTERISTICS:

- Must have receptive and expressive English language skills

- Patients with a history of severe or profound mental retardation (i.e., IQ < 50) are
not eligible for enrollment

- Children with a prior history of attention-deficit hyperactivity disorder (ADHD)
or a specific learning disability (e.g., dyslexia) are eligible for this study

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics
Sponsor:
Children's Oncology Group
National Cancer Institute (NCI)
Dates:
September 2008
Last Updated:
April 10, 2012
Study HIC#:
0909005708

Clinicaltrials.gov ID: NCT00772200